Insulet (PODD) Stock Forecast & Price Target

Insulet is supported by a durable franchise in Omnipod, a tubeless insulin-delivery platform that has expanded to more than 600,000 patients worldwide and still benefits from strong U.S. and international demand, with 2Q revenue of $801.7 million and adjusted EPS of $1.66 both beating expectations. Its fundamentals remain attractive because gross margin of 72.9% and operating margin of 19.3% showed operating leverage, while management continues to target 20% CAGR revenue growth and 100 bps annual adjusted operating margin expansion through 2028. Although U.S. Type 2 retention and newer tubeless entrants create near-term pressure, the company’s pharmacy distribution model, international footprint, and over $1 billion R&D plan for Omnipod 5, Omnipod 6, and a Fully Closed-Loop system support long-term share gains.

Insulet is facing a weakening fundamental setup as U.S. Omnipod growth is expected to decelerate over the next 2-3 quarters, with management trimming full-year U.S. Omnipod growth guidance to 17%-19% cc from 20%-22% cc after Q2 revenue of $801.7M still failed to offset softer utilization and retention trends in the U.S. Type 2 population. The outlook is further pressured by churn concentrated in the first ~90 days of onboarding, uncertainty around whether management’s retention initiatives will work, and a rising competitive threat from tubed and future patch pump rivals that could erode market share and compress margins, especially given that over 98% of revenue comes from Omnipod. With international growth and profitability still positive, the stock remains attractive only to the extent those strengths can outpace execution risk, but the broader multiple looks vulnerable as lower estimates, GLP-1 pressure on insulin needs, and regulatory, cybersecurity, and supply-chain exposures keep the business in a “penalty box” longer.